AstraZeneca cutbacks underscore outsourcing movement

AstraZeneca's decision to cut another 2,200 jobs out of its R&D ops is underscoring a shift from in-house work to a greater reliance on external ties. As AstraZeneca ($AZN) finds itself under severe pressure from falling profits, the pharma giant has decided to go "virtual" on its neuroscience work. And that will speed the industry trend toward outsourcing more discovery and development work to its academic and industry partners. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.